Sprint (NYSE:S): Janco’s calculations indicate that Sprint shareholders will receive $7.51 per share upon the closing of the deal with SoftBank, which the firm expects to happen on Tuesday, June 25th. The firm views upside to $7.51 from current levels as attractive, and keeps a Buy rating on Sprint shares.
Vanda Pharmaceuticals (NASDAQ:VNDA): Following meetings with management, Lazard believes with increased confidence that tasimelteon will gain FDA approval, and is also more confident in the company’s outlook. The firm would use weakness to aggressively to buy shares, and reiterates its Buy rating.
Gannett (NYSE:GCI): Barrington has raised its price target on Gannett to $31 from $25 to better reflect the acquisition of Belo, and believes the deal transforms the mix of the company’s operations with favorable implications for the valuation multiple. It keeps an Outperform rating on shares.
Sarepta Therapeutics (NASDAQ:SRPT): Piper Jafffray believes the continued benefit of eteplirsen in Duchenne muscular dystrophy at 84 weeks supports accelerated approval of the drug by the FDA, and the firm keeps its Overweight rating and price target of $50 as a result.